Sex and genetic associations with cerebrospinal fluid dopamine and metabolite production after severe traumatic brain injury

Restricted access

Object

Dopamine (DA) pathways have been implicated in cognitive deficits after traumatic brain injury (TBI). Both sex and the dopamine transporter (DAT) 3′ variable number of tandem repeat polymorphism have been associated with differences in DAT protein density, and DAT protein affects both presynaptic DA release, through reverse transport, and DA reuptake. Catecholamines and associated metabolites are subject to autooxidation, resulting in the formation of reactive oxygen species that may contribute to subsequent oxidative injury. The purpose of this study was to determine associations between factors that affect DAT expression and cerebrospinal fluid (CSF) DA and metabolite levels after severe TBI.

Methods

Sixty-three patients with severe TBI (Glasgow Coma Scale score ≤ 8) were evaluated. The patients' genotypes were obtained using previously banked samples of CSF, and serial CSF samples (416 samples) were used to evaluate DA and metabolite levels. High-performance liquid chromatography was used to determine CSF levels of DA, 3,4-dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA) during the first 5 days after injury.

Mixed-effects multivariate regression modeling revealed that patients with the DAT 10/10 genotype had higher CSF DA levels than patients with either the DAT 9/9 or DAT 9/10 genotypes (p = 0.009). Females with the DAT 10/10 genotype had higher CSF DA levels than females with the DAT 9/9 or DAT 9/10 genotypes, and sex was associated with higher DOPAC levels (p = 0.004). Inotrope administration also contributed to higher DA levels (p = 0.002).

Conclusions

In addition to systemic administration of DA, inherent factors such as sex and DAT genotype affect post-TBI CSF DA and DA metabolite levels, a phenomenon that may modulate susceptibility to DA-mediated oxidative injury.

Abbreviations used in this paper:CBF = cerebral blood flow; COMT = catechol-O-methyltransferase; CPP = cerebral perfusion pressure; CSF = cerebrospinal fluid; CT = computed tomography; DA = dopamine; DAT = DA transporter; DOPAC = 3,4-dihydroxy-phenylacetic acid; EVD = extraventricular drain; GCS = Glasgow Coma Scale; HPLC = high-performance liquid chromatography; HVA = homovanillic acid; ICP = intracranial pressure; MAO = monoamine oxidase; PCR = polymerase chain reaction; SEM = standard error of the mean; TBI = traumatic brain injury; VNTR = variable number tandem repeat.

Article Information

Address reprint requests to: Amy K. Wagner, M.D., Department of Physical Medicine and Rehabilitation, University of Pittsburgh, 3471 Fifth Avenue, Suite No. 202, Pittsburgh, Pennsylvania 15213. email: wagnerak@upmc.edu.

© AANS, except where prohibited by US copyright law.

Headings

Figures

  • View in gallery

    Bar graphs demonstrating the adjusted mean values from the multivariate analysis of DA by time after severe TBI (upper) and by treatment and systemic administration of inotropes (lower) (*p < 0.05, compared with both Day 1 values [upper] and values with systemic administration of inotropes [lower]). DA_No = no inotrope administration; DA_Yes = inotrope administration.

  • View in gallery

    Graph depicting the adjusted mean values from the multivariate analysis of DA by sex and genotype (*p < 0.05, compared with values for females with the DAT 10/10 genotype).

  • View in gallery

    Bar graphs showing the adjusted mean values from the multivariate analysis of DOPAC by time after severe TBI (upper) and by sex, treatment, genotype, and systemic administration of inotropes (lower) (*p < 0.05, compared with values for females and values with hypothermia treatment).

  • View in gallery

    Graphs illustrating the adjusted mean values from the multivariate analysis of HVA by time after severe TBI (upper) and by sex, treatment, genotype, and systemic administration of ino-tropes (lower) (*p < 0.05, compared with Day 1 values).

  • View in gallery

    Bar graphs depicting the adjusted mean values from the multivariate analysis of the ratio of DOPAC to DA by time after severe TBI (upper) and by sex, treatment, genotype, and systemic administration of inotropes (lower) (*p < 0.05, compared with both Day 1 values [upper] and values with no systemic administration of inotropes [lower]).

  • View in gallery

    Graphs demonstrating the adjusted mean values from the multivariate analysis of the ratio of HVA to DA by time after severe TBI (upper) and by sex, treatment, genotype, and systematic administration of inotropes (lower) (*p < 0.05, compared with values for patients with the DAT 9/9 and DAT 9/10 genotypes and values with no systemic administration of inotropes).

References

1

Agnati LFBjelke BFuxe K: Volume versus wiring transmission in the brain: a new theoretical frame for neuropsychopharmacology. Med Res Rev 15:33451995

2

Beaumont AHayasaki KMarmarou ABarzo PFatouros PCorwin F: Contrasting effects of dopamine therapy in experimental brain injury. J Neurotrauma 18:1359 13722001

3

Becker JB: Gender differences in dopaminergic function in striatum and nucleus accumbens. Pharmacol Biochem Behav 64:8038121999

4

Borland LMMichael AC: Voltammetric study of the control of striatal dopamine release by glutamate. J Neurochem 91:2202292004

5

Bullock RChesnut RMClifton GGhajar JMarion DWNarayan RK: Guidelines for the management of severe head injury. Brain Trauma Foundation Eur J Emerg Med 3:1091271996

6

Clifton GLMiller ERChoi SCLevin HSMcCauley SSmith KR Jr: Lack of effect of induction of hypothermia after acute brain injury. N Engl J Med 344:5565632001

7

Cook EH JrStein MAKrasowski MDCox NJOlkon DMKieffer JE: Association of attention-deficit disorder and the dopamine transporter gene. Am J Hum Genet 56:9939981995

8

Daws LCCallaghan PDMoron JAKahlig KMShippenberg TSJavitch JA: Cocaine increases dopamine uptake and cell surface expression of dopamine transporters. Biochem Biophys Res Commun 290:154515502002

9

Dixon CEKraus MFKline AEMa XYan HQGriffith RG: Amantadine improves water maze performance without affecting motor behavior following traumatic brain injury in rats. Restor Neurol Neurosci 14:2852941999

10

Dluzen DE: Neuroprotective effects of estrogen upon the nigrostriatal dopaminergic system. J Neurocytol 29:3873992000

11

Donnemiller EBrenneis CWissel JScherfler CPoewe WRiccabona G: Impaired dopaminergic neurotransmission in patients with traumatic brain injury: a SPECT study using 123I-beta-CIT and 123I-IBZM. Eur J Nucl Med 27:141014142000

12

Doucette-Stamm LABlakely DJTian JMockus SMao JI: Population genetic study of the human dopamine transporter gene (DAT1). Genet Epidemiol 12:3033081995

13

Engelborghs SMarescau BDe Deyn PP: Amino acids and biogenic amines in cerebrospinal fluid of patients with Parkinson's disease. Neurochem Res 28:114511502003

14

Gardiner SAMorrison MFMozley PDMozley LHBrensinger CBilker W: Pilot study on the effect of estrogen replacement therapy on brain dopamine transporter availability in healthy postmenopausal women. Am J Geriatr Psychiatry 12:6216302004

15

Garris PACiolkowski ELPastore PWightman RM: Efflux of dopamine from the synaptic cleft in the nucleus accumbens of the rat brain. J Neurosci 14:608460931994

16

Gerevich ZTretter LAdam-Vizi VBaranyi MKiss JPZelles T: Analysis of high intracellular [Na+]-induced release of [3H]noradrenaline in rat hippocampal slices. Neuroscience 104:7617682001

17

Gerlach MXiao AYKuhn WLehnfeld RWaldmeier PSontag KH: The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in L-DOPA/carbidopa treated rats. J Neural Transm 108:1892042001

18

Giros BJaber MJones SRWightman RMCaron MG: Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379:6066121996

19

Gulley JMZahniser NR: Rapid regulation of dopamine transporter function by substrates, blockers, and presynaptic receptor ligands. Eur J Pharmacol 479:1391522003

20

Hastings TGLewis DAZigmond MJ: Reactive dopamine metabolites and neurotoxicity: implications for Parkinson's disease. Adv Exp Med Biol 387:971061996

21

Heinz AGoldman DJones DWPalmour RHommer DGorey JG: Genotype influences in vivo dopamine transporter availability in human striatum. Neuropsychopharmacology 22:1331392000

22

Horn AS: Dopamine uptake: a review of progress in the last decade. Prog Neurobiol 34:3874001990

23

Jiang HXie TRamsden DBHo SL: Human catechol-O-methyltransferase down-regulation by estradiol. Neuropharmacology 45:101110182003

24

Jones SRGainetdinov RRJaber MGiros BWightman RMCarom MG: Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc Natl Acad Sci U S A 95:402940341998

25

Jonsson EGNorton NGustavsson JPOreland LOwen MJSedvall GC: A promoter polymorphism in the monoamine oxidase A gene and its relationships to monoamine metabolite concentrations in CSF of healthy volunteers. J Psychiatr Res 34:2392442000

26

Kelly SJOstrowski NLWilson MA: Gender differences in brain and behavior: hormonal and neural bases. Pharmacol Biochem Behav 64:6556641999

27

Khoshbouei HWang HLechleiter JDJavitch JAGalli A: Amphetamine-induced dopamine efflux. A voltage-sensitive and intracellular Na+-dependant mechanism. J Biol Chem 278:12070120772003

28

Kline AEMassucci JLMarion DWDixon CE: Attenuation of working memory and spatial acquisition deficits after a delayed and chronic bromocriptine treatment regimen in rats subjected to traumatic brain injury by controlled cortical impact. J Neurotrauma 19:4154252002

29

Kline AEYan HQBao JMarion DWDixon CE: Chronic methylphenidate treatment enhances water maze performance following traumatic brain injury in rats. Neurosci Lett 280:1631662000

30

Krause KHDresel SHKrause JKung HFTatsch K: Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography. Neurosci Lett 285:1071102000

31

Kroppenstedt SNStover JFUnterberg AW: Effects of dopamine on posttraumatic cerebral blood flow, brain edema, and cerebrospinal fluid glutamate and hypoxanthine concentrations. Crit Care Med 28:379237982000

32

Lambert GNaredi SEden ERydenhag BFriberg P: Monoamine metabolism and sympathetic nervous activation following subarachnoid haemorrhage: influence of gender and hydrocephalus. Brain Res Bull 58:77822002

33

Laranjinha JCadenas E: Oxidation of DOPAC by nitric oxide: effect of superoxide dismutase. J Neurochem 81:8929002002

34

Lavalaye JBooij JReneman LHabraken JBvan Royen EA: Effect of age and gender on dopamine transporter imaging with [123I]FP-CIT SPET in healthy volunteers. Eur J Nucl Med 27:8678692000

35

Massucci JLKline AEMa XZafonte RDDixon CE: Time dependent alterations in dopamine tissue levels and metabolism after experimental traumatic brain injury in rats. Neurosci Lett 372:1271312004

36

McEwen B: Estrogen actions throughout the brain. Recent Prog Horm Res 57:3573842002

37

McIntosh TKYu TGennarelli TA: Alterations in regional brain catecholamine concentrations after experimental brain injury in the rat. J Neurochem 63:142614331994

38

Michelhaugh SKFiskerstrand CLovejoy EBannon MJQuinn JP: The dopamine transporter gene (SLC6A3) variable number of tandem repeats domain enhances transcription in dopamine neurons. J Neurochem 79:103310382001

39

Morissette MDi Paolo T: Sex and estrous cycle variations of rat striatal dopamine uptake sites. Neuroendocrinology 58:16221993

40

Newcorn JH: New treatments and approaches for attention deficit hyperactivity disorder. Curr Psychiatry Rep 3:87912001

41

Nirenberg MJChan JPohorille AVaughan RAUhl GRKuhar MJ: The dopamine transporter: comparative ultrastructure of dopaminergic axons in limbic and motor compartments of the nucleus accumbens. J Neurosci 17:689969071997

42

Oechsner MBuhmann CStrauss JStuerenberg HJ: COMT-inhibition increases serum levels of dihydroxyphenylacetic acid (DOPAC) in patients with advanced Parkinson's disease. J Neural Transm 109:69752002

43

Plenger PMDixon CECastillo RMFrankowski RFYablon SALevin HS: Subacute methylphenidate treatment for moderate to moderately severe traumatic brain injury: a preliminary double-blind placebo-controlled study. Arch Phys Med Rehabil 77:5365401996

44

Porta MBareggi SRCollice MAssael BMSelenati ACalderini G: Homovanillic acid and 5-hydroxyindole-acetic acid in the CSF of patients after a severe head injury. II Ventricular CSF concentrations in acute brain post-traumatic syndromes. Eur Neurol 13:5455541975

45

Ract CVigue BBodjarian NMazoit JXSamii KTadie M: Comparison of dopamine and norepinephrine after traumatic brain injury and hypoxic-hypotensive insult. J Neurotrauma 18:124712542001

46

Raiteri MCerrito FCervoni AMDel Carmine RRibera MTLevi G: Release of dopamine from striatal synaptosomes. Ann Ist Super Sanita 14:971101978

47

Rivest RFalardeau PDi Paolo T: Brain dopamine transporter: gender differences and effect of chronic haloperidol. Brain Res 692:2692721995

48

Sesack SRHawrylak VAMatus CGuido MALevey AI: Dopamine axon varicosities in the prelimbic division of the rat pre-frontal cortex exhibit sparse immunoreactivity for the dopamine transporter. J Neurosci 18:269727081998

49

Smith TSParker WD JrBennett JP Jr: L-dopa increases nigral production of hydroxyl radicals in vivo: potential L-dopa toxicity?. Neuroreport 5:100910111994

50

Swanson JMFlodman PKennedy JSpence MAMoyzis RSchuck S: Dopamine genes and ADHD. Neurosci Biobehav Rev 24:21252000

51

Vecht CJvan Woerkom CATeelken AWMinderhoud JM: Homovanillic acid and 5-hydroxyindoleacetic acid cerebrospinal fluid levels. A study with and without probenecid administration of their relationship to the state of consciousness after head injury. Arch Neurol 32:7927971975

52

Wagner AKChen XKline AELi YZafonte RDDixon CE: Gender and environmental enrichment impact dopamine transporter expression after experimental traumatic brain injury. Exp Neurol 195:4754832005

53

Wagner AKSokoloski JERen DChen XKhan ASZafonte RD: Controlled cortical impact injury affects dopaminergic transmission in the rat striatum. J Neurochem 95:4574652005

54

Whyte JHart TSchuster KFleming MPolansky MCoslett HB: Effects of methylphenidate on attentional function after traumatic brain injury. A randomized, placebo-controlled trial. Am J Phys Med Rehabil 76:4404501997

55

Xie THo SLRamsden D: Characterization and implications of estrogenic down-regulation of human catechol-O-methyltransferase gene transcription. Mol Pharmacol 56:31381999

56

Yan HQKline AEMa XHooghe-Peters ELMarion DWDixon CE: Tyrosine hydroxylase, but not dopamine beta-hydroxylase, is increased in rat frontal cortex after traumatic brain injury. Neuroreport 12:232323272001

57

Yates CMTsementzis SAWilson H: Amine metabolites in ventricular cerebrospinal fluid in coma. J Neurol Neurosurg Psychiatry 42:8878911979

58

Youdim MRiederer PF: A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease. Neurology 63:2 SupplS32S352004

59

Zhang HZhai SDLi YMChen LR: Effect of different sample pretreatment methods on the concentrations of excitatory amino acids in cerebrospinal fluid determined by high-performance liquid chromatography. J Chromotogr B Analyt Technol Biomed Life Sci 784:1311352003

TrendMD

Metrics

Metrics

All Time Past Year Past 30 Days
Abstract Views 96 96 35
Full Text Views 147 147 9
PDF Downloads 78 78 5
EPUB Downloads 0 0 0

PubMed

Google Scholar